home / stock / sny / sny articles

SNY Articles, Sanofi - From 02/01/24

Stock Information
Company Name: Sanofi
Stock Symbol: SNY
Market: NASDAQ
Website: sanofi.com
Menu
SNY SNY Quote SNY Short SNY News SNY Articles SNY Message Board
Get SNY Alerts

News, Short Squeeze, Breakout and More Instantly...
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session | Benzinga

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected ...
French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs | Benzinga

Sanofi SA (NASDAQ:SNY) says its fourth-quarter operating income fell 5.2% to €2.6 billion, up 5.3% on constant currency. Revenues ...

Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year | Benzinga

With the Fed decision now in the rearview mirror, sentiment appears to have taken a turn for the better on the hopes of receiving strong earnings r...

MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session | Benzinga

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday. Shares of MaxLinear, Inc. (NYSE: MXL) s...
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? | Benzinga

The past week’s earnings were bordering on the negative, impacting trader sentiment, and the focus now shifts to the unfolding week that woul...

Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation | Benzinga

Thursday, the FDA approved Regeneron Pharmaceutical Inc (NASDAQ:REGN) / Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for...

French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B | Benzinga

Sanofi SA (NASDAQ:SNY) has agreed to acquire assets and liabilities associated with Inhibrx Inc’s (NASDAQ:INBX) INBRX-101, an ...
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project | Benzinga

In a strategic move to bolster its rare disease business, Sanofi SA (NASDAQ:SNY) has agreed to acquire the drug development project INBRX-101 from ...

Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades | Benzinga

HC Wainwright has downgraded Aclaris Therapeutics Inc (NASDAQ:ACRS). Earlier this month, the company released topline results from its Ph...

Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation | Benzinga

French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in a...
Previous 10 Next 10